DIA会员及用户请点击登录

登录

忘记用户 ID? or 忘记密码?

Not a Member?

创建账户并加入。

Walter E. Washington Convention Center

2015 年 06 月 14 日 2:30 下午 - 2015 年 06 月 18 日 6:45 下午

801 Mount Vernon Place, NW, , Washington, DC 20001-3614 , USA

DIA 2015 51st Annual Meeting: Develop. Innovate. Advance.

Full conference and one-day registrants will have access to presentation PDFs through Friday, December 18, 2015 <A href="http://www.diaglobal.org/Flagship-Meetings/DIA-Annual-Meeting/Meeting-Program/ePac-Presentations-Access.aspx">Review Presentations </A>

An Insider’s View of Cooperation Between the EMA and CDER/FDA: Question Time

Session Chair(s)

Sabine  Haubenreisser, PhD, MSc

Sabine Haubenreisser, PhD, MSc

Principal Scientific Administrator, Stakeholders and Communication Division

European Medicines Agency, Netherlands

Sandra  Kweder, MD

Sandra Kweder, MD

Principal, Drug and Biological Products

ELIQUENT Life Sciences, United States

New this year! Join us for this unique opportunity that includes members from EMA and CDER/FDA Leadership. This first of its kind forum will provide an opportunity for both agencies to discuss and explore at a roundtable discussion areas covered by the EMA/FDA confidentiality arrangements and discuss how both agencies contribute to global development and supervision of medicines. Experts from both agencies who have been at the forefront of EMA/CDER/FDA collaboration will explore topics such as pharmacovigilance, adaptive pathways, quality by design, and patient involvement in the development of medicines.

The audience will be invited to submit questions of general interest. Please come prepared with your questions for the EMA/CDER Question Time panel. You may submit questions and topics of interest in advance to annualmeetingprogram@diaglobal.org, and include “EMA/CDER/FDA Question Time” in the subject line.

Learning Objective : Summarize key issues discussed by EMA and CDER/FDA; Discuss the areas covered under the bilateral cooperation between EMA and FDA aimed at bringing new medicines to patients throughout the world while assuring consistent standards of quality, efficacy and safety; Identify how to engage both agencies in the development of a medicine at the same time.

Speaker(s)

Gerald  Dal Pan, MD, MHS

Panelist

Gerald Dal Pan, MD, MHS

FDA, United States

Director, Office of Surveillance and Epidemiology, CDER

Christine  Moore, PhD

Panelist

Christine Moore, PhD

Organon & Co., United States

Executive Director, Global External Advocacy and Standards

Theresa  Mullin, PhD

Panelist

Theresa Mullin, PhD

FDA, United States

Associate Center Director - CDER

Robert J. Temple, MD

Panelist

Robert J. Temple, MD

FDA, United States

Senior Advisor for Clinical Science, OCD and Immediate Office, OND, CDER

Enrica  Alteri, MD

Panelist

Enrica Alteri, MD

European Medicines Agency, Netherlands

Head, Human Medicines Research and Development Support Division

Peter Richard Arlett, MD, FFPM, FRCP

Panelist

Peter Richard Arlett, MD, FFPM, FRCP

European Medicines Agency, Netherlands

Head Data Analytics and Methods Task Force

Emer  Cooke, MBA, MSc

Panelist

Emer Cooke, MBA, MSc

European Medicines Agency, Netherlands

Chair, ICMRA; Executive Director

注册方法

Registration override should work.

获得信息并保持参与

不要错失任何机会——请加入我们的邮件列表,了解DIA的观点和事件。